- Home
- KLTO vs RLMD Comparison
KLTO vs RLMD Comparison
Compare KLTO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- RLMD
- Stock Information
- Founded
- KLTO 2019
- RLMD 2004
- Country
- KLTO United States
- RLMD United States
- Employees
- KLTO N/A
- RLMD N/A
- Industry
- KLTO
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- RLMD Health Care
- Exchange
- KLTO NYSE
- RLMD Nasdaq
- Market Cap
- KLTO 9.8M
- RLMD 11.5M
- IPO Year
- KLTO N/A
- RLMD N/A
- Fundamental
- Price
- KLTO $0.38
- RLMD $0.30
- Analyst Decision
- KLTO
- RLMD Hold
- Analyst Count
- KLTO 0
- RLMD 4
- Target Price
- KLTO N/A
- RLMD $4.25
- AVG Volume (30 Days)
- KLTO 185.8K
- RLMD 2.1M
- Earning Date
- KLTO 03-04-2025
- RLMD 03-18-2025
- Dividend Yield
- KLTO N/A
- RLMD N/A
- EPS Growth
- KLTO N/A
- RLMD N/A
- EPS
- KLTO N/A
- RLMD N/A
- Revenue
- KLTO N/A
- RLMD N/A
- Revenue This Year
- KLTO N/A
- RLMD N/A
- Revenue Next Year
- KLTO N/A
- RLMD N/A
- P/E Ratio
- KLTO N/A
- RLMD N/A
- Revenue Growth
- KLTO N/A
- RLMD N/A
- 52 Week Low
- KLTO $0.26
- RLMD $0.28
- 52 Week High
- KLTO $13.10
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- RLMD 30.81
- Support Level
- KLTO N/A
- RLMD $0.28
- Resistance Level
- KLTO N/A
- RLMD $0.36
- Average True Range (ATR)
- KLTO 0.00
- RLMD 0.04
- MACD
- KLTO 0.00
- RLMD 0.02
- Stochastic Oscillator
- KLTO 0.00
- RLMD 7.21
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.